Skip to main content
. Author manuscript; available in PMC: 2016 Sep 10.
Published in final edited form as: N Engl J Med. 2016 Mar 10;374(10):940–950. doi: 10.1056/NEJMoa1508380

Figure 2. Survival Benefit for Recipients of Kidney Transplants from HLA-Incompatible Live Donors as Compared with the Two Groups of Matched Controls, According to Donor-Specific Antibody Level.

Figure 2

The survival benefit is shown for transplant recipients who had a positive Luminex assay but a negative flow-cytometric cross-match (Panel A), those who had a positive flow-cytometric cross-match but a negative cytotoxic cross-match (Panel B), and those who had a positive cytotoxic cross-match (Panel C).